Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISCHEMIA trial of high-dose nadroparin after aneurysmal subarachnoid hemorrhage
NL-OMON23094Phase 3Not yet recruiting
- Sponsor
- Academic Medical Center
- Start
- Jan 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nadroparin in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Academic Medical Center. Primary endpoint: In-hospital mortality. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
nadroparin
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON23094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23094.